Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of 9.55% and Operating profit at 23.09% over the last 5 years
2
The company has declared Negative results for the last 5 consecutive quarters
3
With ROE of 12.81%, it has a fair valuation with a 2.45 Price to Book Value
4
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
CNY 5,049 Million (Small Cap)
19.00
NA
2.73%
-0.33
11.79%
1.96
Revenue and Profits:
Net Sales:
818 Million
(Quarterly Results - Dec 2025)
Net Profit:
77 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-7.78%
0%
-7.78%
6 Months
-18.88%
0%
-18.88%
1 Year
-28.97%
0%
-28.97%
2 Years
-38.45%
0%
-38.45%
3 Years
-51.94%
0%
-51.94%
4 Years
-46.62%
0%
-46.62%
5 Years
23.06%
0%
23.06%
Jianmin Pharmaceutical Group Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
9.55%
EBIT Growth (5y)
23.09%
EBIT to Interest (avg)
52.74
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.36
Sales to Capital Employed (avg)
1.41
Tax Ratio
14.91%
Dividend Payout Ratio
38.12%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
14.21%
ROE (avg)
18.68%
Valuation key factors
Factor
Value
P/E Ratio
19
Industry P/E
Price to Book Value
2.45
EV to EBIT
34.65
EV to EBITDA
23.64
EV to Capital Employed
3.10
EV to Sales
1.64
PEG Ratio
NA
Dividend Yield
2.24%
ROCE (Latest)
8.94%
ROE (Latest)
12.81%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Mildly Bullish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
Dec'25
Sep'25
Change(%)
Net Sales
818.00
747.30
9.46%
Operating Profit (PBDIT) excl Other Income
70.30
45.30
55.19%
Interest
4.90
2.90
68.97%
Exceptional Items
-3.50
6.00
-158.33%
Consolidate Net Profit
76.60
66.20
15.71%
Operating Profit Margin (Excl OI)
63.10%
35.70%
2.74%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2025 is 9.46% vs -18.10% in Sep 2025
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2025 is 15.71% vs -40.52% in Sep 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
3,351.40
3,482.70
-3.77%
Operating Profit (PBDIT) excl Other Income
302.50
180.60
67.50%
Interest
14.30
14.00
2.14%
Exceptional Items
16.70
27.90
-40.14%
Consolidate Net Profit
365.20
367.70
-0.68%
Operating Profit Margin (Excl OI)
68.80%
31.60%
3.72%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -3.77% vs -16.76% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -0.68% vs -29.72% in Dec 2024
About Jianmin Pharmaceutical Group Co., Ltd. 
Jianmin Pharmaceutical Group Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






